The tyrosine kinase inhibitor dasatinib suppresses cytokine production by plasmacytoid dendritic cells by targeting endosomal transport of CpG DNA

European Journal of Immunology

Volumn 43, Issue 1, 2013, Pages 93-103

  Fujita, Haruyuki ^a   Kitawaki, Toshio ^a   Sato, Takayuki ^a   Maeda, Takahiro ^b   Kamihira, Shimeru ^b   Takaori Kondo, Akifumi ^a   Kadowaki, Norimitsu ^a,c  

^a KYOTO UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Dasatinib; Interferon; Plasmacytoid dendritic cells (pDCs); TLR9

Indexed keywords

ALPHA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DASATINIB; DNA; IMATINIB; NILOTINIB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; ENDOSOME; HUMAN; IN VIVO STUDY; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; ENDOSOMES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 84872485137     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242699     Document Type: Article

References (39)

1. Liu, Y.-J., IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005. 23: 275-306.
2. Gilliet, M., Cao, W. and Liu, Y.-J., Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008. 8: 594-606.
3. Ganguly, D., Chamilos, G., Lande, R., Gregorio, J., Meller, S., Facchinetti, V., Homey, B. et al., Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J. Exp. Med. 2009. 206: 1983-1994.
4. Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A. and Griffin, J. D., Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 2007. 7: 345-356.
5. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S. et al., Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004. 47: 6658-6661.
6. Schade, A. E., Schieven, G. L., Townsend, R., Jankowska, A. M., Susulic, V., Zhang, R., Szpurka, H. and Maciejewski, J. P., Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008. 111: 1366-1377.
7. Fei, F., Yu, Y., Schmitt, A., Rojewski, M. T., Chen, B., Greiner, J., Götz, M. et al., Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens. Exp. Hematol. 2008. 36: 1297-1308.
8. Blake, S. J., Bruce Lyons, A., Fraser, C. K., Hayball, J. D. and Hughes, T. P., Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008. 111: 4415-4416.
9. Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R. and Krusch, M., The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int. J. Cancer 2010. 127: 2119-2128.
10. Manley, P. W., Stiefl, N., Cowan-Jacob, S. W., Kaufman, S., Mestan, J., Wartmann, M., Wiesmann, M. et al., Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg. Med. Chem. 2010. 18: 6977-6986.
11. Honda, K., Ohba, Y., Yanai, H., Negishi, H., Mizutani, T., Takaoka, A., Taya, C. and Taniguchi, T., Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005. 434: 1035-1040.
12. Guiducci, C., Ott, G., Chan, J. H., Damon, E., Calacsan, C., Matray, T., Lee, K.-D. et al., Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med. 2006. 203: 1999-2008.
13. Krieg, A. M., CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002. 20: 709-760.
14. Kerkmann, M., Costa, L. T., Richter, C., Rothenfusser, S., Battiany, J., Hornung, V., Johnson, J. et al., Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-{alpha} induction by CpG-A in plasmacytoid dendritic cells. J. Biol. Chem. 2005. 280: 8086-8093.
15. Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W. et al., Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007. 449: 564-569.
16. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdorfer, B., Blackwell, S., Ballas, Z. K., Endres, S. et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 2001. 31: 2154-2163.
17. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A. and Connelly, P. A., Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem. 1996. 271: 695-701.
18. Blake, R. A., Broome, M. A., Liu, X., Wu, J., Gishizky, M., Sun, L. and Courtneidge, S. A., SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell. Biol. 2000. 20: 9018-9027.
19. Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K. A., Monks, B. G., Knetter, C. F., Lien, E. et al., TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 2004. 5: 190-198.
20. Hirai, M., Kadowaki, N., Kitawaki, T., Fujita, H., Takaori-Kondo, A., Fukui, R., Miyake, K. et al., Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011. 117: 500-509.
21. Manders, E. M. M., Verbeek, F. J. and Aten, J. A., Measurement of colocalization of objects in dual-color confocal images. J. Microsc. 1993. 169: 375-382.
22. Dunn, K. W., Kamocka, M. M. and McDonald, J. H., A practical guide to evaluating colocalization in biological microscopy. Am. J. Physiol. Cell Physiol. 2011. 300: C723-C742.
23. Costes, S. V., Daelemans, D., Cho, E. H., Dobbin, Z., Pavlakis, G. and Lockett, S., Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 2004. 86: 3993-4003.
24. Kaisho, T. and Tanaka, T., Turning NF-[kappa]B and IRFs on and off in DC. Trends Immunol. 2008. 29: 329-336.
25. Park, B., Brinkmann, M. M., Spooner, E., Lee, C. C., Kim, Y.-M. and Ploegh, H. L., Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 2008. 9: 1407-1414.
26. Maeda, T., Murata, K., Fukushima, T., Sugahara, K., Tsuruda, K., Anami, M., Onimaru, Y. et al., A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma. Int. J. Hematol. 2005. 81: 148-154.
27. Sanjuan, M. A., Rao, N., Lai, K.-T. A., Gu, Y., Sun, S., Fuchs, A., Fung-Leung, W.-P. et al., CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J. Cell Biol. 2006. 172: 1057-1068.
28. Liberali, P., Rämö, P. and Pelkmans, L., Protein kinases: starting a molecular systems view of endocytosis. Annu. Rev. Cell Dev. Biol. 2008. 24: 501-523.
29. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T. et al., Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007. 25: 1035-1044.
30. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I. et al., Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007. 110: 4055-4063.
31. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W. et al., A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008. 26: 127-132.
32. Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L. et al., A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 2010. 6: 291-299.
33. Sasai, M., Linehan, M. M. and Iwasaki, A., Bifurcation of Toll-Like receptor 9 signaling by adaptor protein 3. Science 2010. 329: 1530-1534.
34. Blasius, A. L., Arnold, C. N., Georgel, P., Rutschmann, S., Xia, Y., Lin, P., Ross, C. et al., Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. USA 2010. 107: 19973-19978.
35. Lee, J., Tattoli, I., Wojtal, K. A., Vavricka, S. R., Philpott, D. J. and Girardin, S. E., pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. J. Biol. Chem. 2009. 284: 23818-23829.
36. Di Pietro, S. M., Falcón-Pérez, J. M., Tenza, D., Setty, S. R. G., Marks, M. S., Raposo, G. and Dell'Angelica, E. C., BLOC-1 interacts with BLOC-2 and the AP-3 complex to facilitate protein trafficking on endosomes. Mol. Biol. Cell 2006. 17: 4027-4038.
37. Setty, S. R. G., Tenza, D., Truschel, S. T., Chou, E., Sviderskaya, E. V., Theos, A. C., Lamoreux, M. L. et al., BLOC-1 is required for cargo-specific sorting from vacuolar early endosomes toward lysosome-related organelles. Mol. Biol. Cell 2007. 18: 768-780.
38. Kawamura, K., Kadowaki, N., Kitawaki, T. and Uchiyama, T., Virus-stimulated plasmacytoid dendritic cells induce CD4 +cytotoxic regulatory T cells. Blood 2006. 107: 1031-1038.
39. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L. et al., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 2000. 164: 1617-1624.